Melphalan Tillomed

Melphalan, the active ingredient in Melphalan Tillomed, is an alkylating agent (nitrogen mustard) presented as a intravenous formulation for intravenous use. It treats multiple myeloma, ovarian cancer, melanoma, neuroblastoma and other solid tumors in adult patients.

GNH USA supplies Melphalan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan is an alkylating chemotherapy agent used in the treatment of various malignancies.

- Multiple myeloma: reduces tumor burden and prolongs survival. - Ovarian cancer: incorporated into combination regimens to achieve tumor shrinkage. - Melanoma: employed in high‑dose protocols for metastatic disease. - Neuroblastoma: part of intensive chemotherapy for high‑risk disease. - Other solid tumors: applied where alkylating agents are indicated.

Melphalan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during treatment. - Bone marrow suppression: decreased white cells, red cells, and platelets. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Secondary malignancies: risk of new cancers developing later. - Severe infection: opportunistic infections due to neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

Melphalan requires careful monitoring and specific safety measures before and during therapy.

- Monitor blood counts: perform complete blood count before each cycle. - Assess renal function: check serum creatinine and adjust dose if needed. - Evaluate pulmonary status: obtain baseline lung function tests. - Avoid use in active infection: treat infections prior to administration. - Store at ambient temperature: keep in original container, protect from light and moisture.

Melphalan can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concurrent alkylating agents: additive toxicity. - Live vaccines: increased risk of infection. - High‑dose radiation therapy: enhanced tissue damage.

Moderate Interactions (Monitor Closely): - Antiemetics: may affect melphalan metabolism. - NSAIDs: increase risk of renal toxicity. - G‑CSF agents: may mitigate neutropenia but require dose adjustment.